PACE Forward-Making Pharmacogenomics Testing Available for Real-Life Clinical Utility

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Health Informatics

Background:

• Pharmacogenomics (PGx) has the potential to personalize medication therapy, ensuring optimal drug efficacy and safety.
• Current integration of gene-drug interaction data into electronic health records remains a significant challenge.
• Existing barriers hinder the widespread clinical adoption of PGx for precision medicine.

Purpose of the Study:

• To introduce a preemptive, adaptable, current, and executable (PACE) pharmacogenomic testing strategy.
• To address the human and technological obstacles preventing seamless PGx data integration into patient health records.
• To facilitate the practical implementation of PGx at the point of prescription ordering.

Main Methods:

• Development of the PACE framework for pharmacogenomic testing.
• Evaluation of strategies to overcome barriers in PGx data integration.
• Alignment of PGx testing with clinical practice guidelines and prescription workflows.

Main Results:

• The PACE model offers a viable solution for overcoming implementation challenges in pharmacogenomics.
• Successful integration of PGx data can be achieved through a systematic and adaptable approach.
• Pharmacogenomic testing can be effectively executed at the point of care, optimizing prescribing decisions.

Conclusions:

• Pharmacogenomic testing, when implemented using the PACE framework, can realize the promise of personalized medicine.
• Addressing integration barriers is crucial for leveraging PGx to improve patient outcomes.
• The PACE strategy enables cost-effective and timely application of pharmacogenomics in clinical practice.